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Latent transforming growth factor-a: Structural features and mecha-
nisms of activation. Transforming growth factors-J3 are cytokines with a
wide range of biological effects. They play a pathologic role in inflamma-
tory and fibrosing diseases such as nephrosclerosis. TGF-13s are secreted in
a latent form due to noncovalent association with latency associated
peptide (LAP), which is a homodimer formed from the propeptide region
of TGF-13. LAP is disulfide linked to another protein, latent TGF-f3
binding protein (LTBP). LTBP has features in common with extracellular
matrix proteins, and targets latent TGF-J3 to the matrix. Activation of
latent TGF-13 can be accomplished in vitro by denaturing treatments,
plasmin digestion, ionizing radiation and interaction with throm-
bospondin. The mechanisms by which latent TGF-13 is activated physio-
logically are not well understood. Results to date suggest an important
role for proteases, particularly plasmin, although other mechanisms
probably exist. A general model of activation is proposed in which latent
TGF-13 is released from the extracellular matrix by proteases, localized to
cell surfaces, and activated by cell-associated plasmin.
Transforming growth factors-a (isoforms 1, 2 and 3) are
mammalian cytokines involved in development, proliferation,
angiogenesis, regulation of inflammation, extracellular matrix
production, integrin expression, protease activity and apoptosis [1,
2]. Evidence from animal and clinical studies indicates they play
important etiologic roles in various inflammatory and fibrotic
diseases, including nephrosclerosis [3]. These cytokines belong to
the TGF-/3 superfamily, which in mammals includes Mullerian
inhibitory substance, activins, inhibins and bone morphogenic
proteins, and is characterized by a distinctive "cysteine knot"
structure [4, 5].
The TGF-13s are notable among cytokines because of the
number of ways in which their bioavailability is regulated by
additional proteins. Newly synthesized TGF-13 is released in a
latent form (that is, a form in which it cannot interact with TGF-f3
receptors) due to noncovalent association with the TGF-f3
propeptide homodimer, also termed latency associated peptide
(LAP). TGF-13 must be liberated from this complex before it can
exert its actions, a process termed activation. Latent TGF-13 can
be targeted to the extracellular matrix (ECM) by a second
molecule, latent TGF-13 binding protein (LTBP). One LTBP
monomer is disulfide linked to LAP. Finally, free TGF-13 can
interact with and be inactivated by a number of soluble or matrix
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molecules, including alpha2-macroglobulin, decorin, betaglycan,
heparin, and fucoidan [6—9] These interactions are thought to
prevent TGF-/3 from diffusing from loci of activation and thereby
exerting effects in inappropriate sites. TGF-f3 in plasma is found
almost exclusively bound to alpha2-macrogloblin and presumably
represents previously activated TGF-13 that will be cleared by the
liver [6]. The processes of activation, localization and subsequent
inactivation by extracellular molecules are reminiscent of the
control of protease systems (such as the plasminogen/plasminogen
activator and coagulation systems) in which proteases are acti-
vated when required, concentrated at the cell surface, and inac-
tivated by a variety of soluble inhibitors. As discussed below, there
is evidence that TGF-/3 activation is also localized to cell surfaces.
Conditions under which cells secrete TGF-f3 in a completely
free form have not been described, and the concentration of free
TGF-f3 in equilibrium with the LAP-bound form is probably
physiologically negligible (the apparent Kid of this interaction
being —1 nM) [10]. Thus, activation of latent TGF-13 must be a
major regulatory step controlling TGF-/3 effects. Although a
variety of activation mechanisms have been established in cell
culture and in vitro systems, almost nothing is known about how
TGF-13 is activated in vivo. Indeed, the precise mechanism of
activation in certain cell culture systems remains unknown despite
intense investigation. Why is this a refractory problem? First,
activation of TGF-p can be difficult to detect. Typically, condi-
tioned medium from the cells being tested is employed in
bioassays or immunological assays of active TGF-p. However, if
TGF-/3 is efficiently activated at cell surfaces and rapidly cleared
from the medium by specific receptors, little TGF-13 will remain
free for detection. The detection of active TGF-/3 is even more
difficult in vivo, although recently two techniques for recognizing
active TGF-f3 in tissue sections have been reported [11, 12].
Second, it is likely that there are multiple mechanisms of activa-
tion that may operate simultaneously. Third, a given mechanism
may involve multiple steps (such as release of latent TGF-f3 from
matrix, modification of the latent complex, and association of
latent TGF-f3 with the cell surface), any of which might be
accomplished in more than one fashion. Finally, in a cell culture
system, the activation of TGF-p can lead to a down-regulation of
the activating pathway, as when active TGF-f3 results in increased
levels of plasminogen activator inhibitor-I (PAl-i), leading to
down-regulation of a plasmin-mediated activation pathway [13].
This paper reviews the structure of latent TGF-j3, mechanisms
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Fig. 1. Schematic representation of latent TGF-j The putative tissue transglutaminase-mediated covalent bonding between the N-terminus of LTBP and
the ECM is indicated by a question mark (?). Disulfide bonds between LAP monomers, between TGF-p monomers and between LAP and LTBP are
indicted by thin lines. Carbohydrate residues on LTBP are not shown. Abbreviations are in the text. Symbols are: (I) carbohydrate; ()
mannose-6-phosphate; (0) 8-cysteine domain; (•) EGF-like domain.
of activation identified by our lab and others, and questions that
remain to be addressed.
Structure of latent TGF-13
The free TGF-f3 cytokines are 25-kDa homodimeric proteins.
(Small amounts of TGF-p heterodimers can be detected, such as
in platelets.) TGF-3 associated with LAP is termed the small
latent complex (SLC). If LAP is disulfide linked to latent TGF-f3
binding protein (LTBP), the resultant complex is termed the large
latent complex (LLC). These associations are depicted in Figure
1.
LAP has several important structural features. Like TGF-p,
LAP is a homodimer, which is formed within the secretory
pathway after the removal of a signal sequence and cleavage from
the mature TGF-f3 peptide sequence at a processing site contain-
ing basic amino acids. In addition to rendering TGF-13 latent, LAP
enhances the proper folding and secretion of the cytokine [14].
Other members of the TGF-13 superfamily have similarly sized
propeptide sequences. These sequences have little homology to
the TGF-/3 propeptides, and although they also play a role in the
proper folding and secretion of the active factors [14], no other
functions have been ascribed to them. There are three cysteines
per LAP-I monomer. The LAP-i monomers are thought to be
joined by intrachain disulfide bonds involving the two cysteines
located near the C-termini (at amino acids 223 and 225). A third
cysteine near the N-terminus (amino acid 33) is disulfide-bonded
to LTBP [15]. The other two isoforms of LAP contain three
cysteines in equivalent locations along with two additional cys-
teines of unknown function. Each monomer of LAP (isoform 1)
contains three N-linked carbohydrate residues, two of which
contain mannose-6-phosphate (M6P) [16]. LAP can associate with
the insulin-like growth factor ll/mannose-6-phosphate receptor
(IGF-II/M6PR) [17] via interactions with these M6P residues,
suggesting a mechanism by which latent TGF-/3 can be localized
to cell surfaces. The IGF-I1/M6PR is required for activation of
latent TGF-p in cocultures of endothelial and smooth muscle cells
[181. Because M6P residues target newly synthesized proteins to
the lysosomes, it is important to understand how latent TGF-p
escapes this fate. One possibility being examined in our laboratory
is that LTBP in the LLC masks the M6P residues; alternatively,
TGF-/3 itself or a specific conformation of LAP might mask the
M6P residues within the secretory pathway. Isoforms 1 and 3 of
LAP each contain one arginine-glycine-aspartate (RGD) se-
quence per monomer, which might also function to localize latent
cytokine to the cell surface by binding RGD-recognizing integrins.
Recently, Grainger and colleagues have reported indirect evi-
dence that the RGD sequence in platelet-derived SLC may be
recognized by platelet integrins [19]. However, no other reports
that these RGD sequences are capable of binding integrins have
appeared.
The three dimensional structure of LAP has not been reported,
so information about its interaction with TGF-f3 is indirect.
Recombinant LAP expressed by itself is secreted from mamma-
lian cells and is able to bind and inactivate recombinant TGF-p
[14, 201. We (J.G. Harpel and D.B. Rifkin, unpublished observa-
tions) and others [21] have found that recombinant LAP pro-
duced by insect cells is also active, both in vitro and in vivo.
Mutational analysis indicates that regions near the N-termini are
important for interacting with TGF-/3 [221, and circular dichroism
measurements indicate that recombinant LAP undergoes signifi-
cant conformational change on binding to TGF-p [23].
As discussed below, plasmin can activate latent TGF-f3 (LLC)
by acting on LAP [24, 25]. The exact proteolytic site(s) for this
activation have not been determined. Studies by Lyons et al using
immunoblots with antibodies specific for different regions of LAP
suggest that the site is near the N-terminus [25]. However, a
different site appears to be preferentially cleaved when plasmin
acts on free LAP (J.S. Munger, unpublished observation).
LTBP (now known as LTBP-1, see below) is a 125 to 190 kDa
glycoprotein [26]. The range of observed sizes is thought to be due
to differences in proteolytic processing. In free form, it assumes a
linear shape as revealed by rotary shadowing (P-E. Gleizes, D.R.
Keene and D.B. Rifkin, unpublished observations). It has a
distinctive structure closely related to that of the fibrillins. This
structure consists of multiple epidermal growth factor (EGF)-like
domains, and four domains that contain up to eight cysteines in a
conserved arrangement. The latter domains, termed eight cysteine
domains (although the first such domain in LTBP contains only 7
cysteines), are unique to the LTBPs and fibrillins. Miyazono et al
have reported that LTBP enhances the secretion of latent TGF-/3
via formation of the LLC [27]. Taipale et al [28] have proposed
the existence of a protease-sensitive "hinge" region. Cleavage at
this site may be involved in protease-mediated release of LLC
from the matrix, with which LTBP-1 can associate (see below).
LTBP-2 and -3 are recently described molecules [29, 301 with
similar structures that can also form LLCs with TGF-/3 1 when
overexpressed in mammalian cells. The relative biological roles of
the three isoforms, including any role they may play as matrix
proteins unassociated with TGF-13, remain unclear. Bonewald and
colleagues have suggested that LTBP-1 has a distinct role as an
ECM protein [31], and conversely have shown that certain cells
can secrete predominantly the SLC form of TGF-/3 [32]. Thus,
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TGF-/3 bioavailability may be governed in part by whether the
LLC is formed and, if so, which LTBP isoform is involved.
Although in most cell systems in which the latent complex has
been defined TGF-13 is found as a LLC containing LTBP-1, in
most in vivo settings and cell culture systems the proteins with
which TGF-/3 is associated remain undefined.
LLC produced by cells in tissue culture is secreted into the
medium and is also incorporated into the matrix. Recently a form
of LTBP-1 with an extended amino terminus due to alternate
mRNA splicing, termed LTBP-1L, has been described [331.
LTBP-1L associates more readily with the matrix than does the
previously described form (LTBP-IS). LTBP can be released from
matrix by protease digestion but not by denaturing treatments [28,
34] (and I. Nunes, unpublished observations), which suggests that
LTBP is covalently linked to the matrix. Work by our laboratory
suggests that this cross-linking may be mediated by the enzyme
tissue transglutaminase (tTGase). As discussed below, inhibitors
of tTGase block TGF-f3 activation by cocultures of endothelial
and smooth muscle cells [35]. Also, Nunes et a! (unpublished
observations) have found that transglutaminase inhibitors and
antibodies to the N-terminus of LTBP-1 block incorporation of
LTBP-1 into the matrix formed by HT1080 fibrosarcoma cells.
Together, these observations suggest that covalent association of
LLC to the ECM is an important context for activation.
Recently, Saharinen et al and Gleizes et al [15, 36] have shown
that the third 8 cysteine domain is necessary and sufficient for the
disulfide bonding of LAP and LTBP-1. The number of bonds
between domain 3 and LAP is not yet known. This is the first
reported function for these domains. These observations suggest
that the eight cysteine domains may be involved in protein-protein
interactions.
Like several other matrix proteins, human LTBP-1 contains an
RGD sequence. However, there are no reports that this sequence
serves as an integrin ligand, and two facts argue that it is
nonfunctional. First, fibrillin-1 contains RGD motifs that can
mediate cell binding [37], but these are located in eight cysteine
domains, whereas the sole RGD sequence in hLTBP-1 is located
in an EGF-Iike domain. Second, the RGD in hLTBP-1 is not
present in the rat homologue of LTBP-1.
How does the intact large latent complex function in activation?
The structural features described above suggest the following
general concepts. First, LTBP acts to target latent TGF-/3 to sites
in the matrix where it remains until activated. (In some cases,
latent TGF-13 may be released as SLC to avoid matrix sequestra-
tion). Latent TGF-/3 can be released from the matrix by limited
proteolysis of LTBP by proteases such as thrombin, chymase,
elastase and plasmin, as might occur during matrix remodeling or
inflammation. Structural features of LAP and/or LTBP might
allow this soluble form of latent TGF-13 to associate with the cell
surface where TGF-13 would be released from LAP. The final
mechanisms for TGF—13 release from LAP are not known, and, as
discussed below, might involve proteolytic and/or nonproteolytic
events.
Activation of latent TGF-f3
How does activation occur? Studies addressing this question
employ either in vitro, cell culture, or in vivo systems. In general,
in vitro experiments reveal only direct activators of latent TGF-p.
In contrast, cell and in vivo systems might identify both prelimi-
nary steps in activation (such as release of matrix-bound TGF-13)
Table 1. Mechanisms of latent TGF-13 activation
In vitro Cell culture In vivo
Nonproteolytic heat
detergents
pH extremes
chaotropes
radiation
thrombospondin-1
deglycosylation
sialic acid, M6P
coculturea
matrix vesicles
radiation?
Proteolytic plasmin
cathepsin D
coculture (plasmin)a
other proteases
plasmin?
a Activation by cocultures of endothelial cells with pericytes or smooth
muscle cells; activation involves proteolytic and nonproteolytic events.
and activation per se. One cannot necessarily distinguish between
indirect and direct effects on activation. For example, the obser-
vation that inhibitors of plasmin block activation in a cell culture
system does not distinguish between the action of plasmin to
release latent TGF-p from matrix reservoirs and the direct
cleavage of LAP resulting in activation. Table 1 lists known
conditions for activating TGF-13. These conditions are briefly
discussed below.
Denaturing conditions
TGF-13 is more stable than LAP under a number of denaturing
conditions [38]. Thus, latent TGF-f3 can be activated by denatur-
ing by heat, chaotropes, detergents, and extremes of pH. These
conditions are useful in assays of total TGF-; heating and
acidification are commonly used for this purpose. It is unlikely
that such mechanisms operate in vivo, with two possible excep-
tions. First, Lyons, Keski-Oja and Moses [24] reported that some
activation occurs in vitro in the pH 4 to 5 range (albeit less than at
pH 2), which suggests that activation of TGF-13 might occur in
physiologically acidified zones, such as along the ruffled border of
the osteoclast. Indeed, activation by cultured osteoclasts occurs
[39, 40]. Second, TGF-f3 might be activated in areas of thermal
burns.
Radiation
Barcellos-Hoff and Dix [41] have found that reactive oxygen
species, generated by either ionizing radiation or metal-catalyzed
ascorbate oxidation, can activate latent TGF-/3. This suggests that
there is a redox-sensitive element in LAP, which is yet to be
defined but might be one or more of the cysteines. These in vitro
results are consistent with immunologic evidence of rapid (within
1 hr) activation of TGF-f3 in irradiated breast tissue [12]. Whether
this system operates in vivo only under the extreme conditions of
ionizing radiation or also under physiological variations in tissue
redox potential needs to be determined.
Thrombospondin
Thrombospondin-1 (TSP-i) is a trimer of disulfide-linked 180-
kDa subunits found at high concentration in platelet alpha-
granules and also produced by a number of other cell types. It is
an adhesive protein with a number of domains available for
binding to cell surface or matrix proteins. Murphy-Ullrich and
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colleagues have reported that TSP-i isolated from human plate-
lets is tightly associated with TGF-13 that can be released at high
pH, and that latent TGF-p is nonproteolytically activated by
TSP-i in vitro [42]. TSP-i also activates TGF-J3 in cell culture
assays when added to endothelial cells. This activation appears to
be related to binding of TSP-i to latent TGF-/3 at the so-called
type I (properdin-like) domains of TSP-i [43]. There may also be
an important interaction with LAP as antibodies against a region
near the N-terminus of the LAP monomers block activation.
These results have been extended by Souchelnitskiy, Chambaz
and Feige [441, who have shown that both TSP-i and -2 can
activate LLC, and that neither can activate TGF-13 bound to
alpha2-macroglobulin.
These observations suggest that TSP may play an important
role as an activator or stabilizer of TGF-/3. However, other
observations suggest that the situation is more complex. For
example, cultures of sparse, rapidly growing cells produce more
TSP-i than confluent, growth-arrested cells; however, because
TGF-J3 inhibits the proliferation of these cell types one might
expect the opposite relationship between proliferation and TSP-i
levels [45]. Also, although both TSP-i and TGF-f3 can affect
angiogenesis, some reported effects of TSP-i on angiogeriesis are
independent of TGF-f3 [45].
Deglycosylation
Miyazono and Heldin reported that latent TGF-f3 (LLC) can be
activated by enzymatic removal of carbohydrate moieties on LAP
[46]. This suggests that carbohydrate structures are important in
the interaction of LAP and TGF-13 and, in fact, competing
concentrations of sialic acid and M6P are also able to activate
latent TGF-f3 [46]. It is not known if this represents a physiological
activation mechanism. However, cells such as activated macro-
phages, in which sialidase activity is induced, might use such a
mechanism.
Proteases
Lyons et a! showed that two proteases, plasmin and the
lysosomal serine protease cathepsin D, can activate LLC in vitro
[24]. Some LLC remained unactivated in these experiments,
suggesting that there are two or more populations of LLC with
differing sensitivities to plasmin. Immunoblotting with site-specific
antibodies suggested that the important proteolytic event occurs
near the N-terminus [25]. Taipale et al have shown that several
proteases (plasmin, thrombin, neutrophil elastase and mast cell
chymase) can readily release LTBP (as latent TGF-/3) from matrix
produced by cells in tissue culture [47]. This occurs by cleavage at
a specific protease-sensitive site in LTBP, an event that separates
a truncated form of LLC from the N-terminus of LTBP that
remains bound to the matrix.
Thus, plasmin might promote TGF-J3 activation in two ways: by
liberating a form of latent TGF-13 from storage sites in the matrix,
and by directly activating this latent TGF-f3. What are the relative
rates of these different actions by plasmin? Experiments in our
laboratory, using recombinant LLC in solution exposed to plas-
mm, indicate that the truncation of LTBP occurs much more
rapidly than the degradation of LAP (J.S. Munger, unpublished
observations). Further questions need to be answered to under-
stand the role of plasmin in activation; for example, can LAP's
sensitivity to plasmin be modulated, perhaps by conformational
changes induced by binding to cell surface proteins?
Cocultures of endothelial cells and smooth muscle cells
Antonelli-Orlidge and colleagues reported in 1989 that cocul-
tures of capillary endothelial cells and pericytes activate latent
TGF-/3 produced by the cells; monocultures of the same cells
produced only latent TGF-p, and close cell contact was required
[48]. Our laboratory obtained similar results, using an assay
system in which serum-free conditioned medium from mono- or
cocultures of endothelial cells and smooth muscle cells was
assayed for its ability to inhibit endothelial cell migration in a
TGF--dependent manner [49]. This system has now been studied
extensively.
Several results indicate that plasmin is required for activation in
this coculture system. Both plasmin inhibitors and depletion of
plasminogen from the culture medium block activation [i3].
(Note that because the assays are done in serum-free conditions,
the source of plasminogen used in activation is cell- or matrix-
associated plasminogen derived from previous culture in serum-
containing medium.) Lipoprotein (a), which contains regions
homologous to plasminogen and can displace plasminogen from
cellular binding sites, also blocks activation [50]. Our results are
consistent with both a direct activating effect of plasmin on latent
TGF-f3, and indirect effects (such as release of latent TGF-/3 from
matrix stores). The major effect of plasmin is not likely to be
simply the liberation of latent TGF-13 from matrix, because the
conditioned medium of the cultures already contains concentra-
tions of soluble latent TGF-13 in excess of 1 ng/ml. However, the
truncated, released form of LLC may be more readily activatable
than the LLC. Because of increased PAl-i levels due to TGF-f3,
this activation system is self-regulating. TGF-13 is formed within
the first 12 hours of the coculture. Within the same time frame,
PAT-i levels increase 20-fold, and no further TGF-p activation
occurs after this period unless antibodies to PAl-i are added.
There are three other requirements for activation in this
system. First, LTBP-1 is necessary since antibodies to LTBP-i,
and exogenously added excess recombinant LTBP-i, block acti-
vation [51]. The underlying mechanism is not understood. Second,
interference with ligand binding to the IGF-II/M6PR by addition
of M6P or antibodies to the receptor blocks activation [i8]. Again,
the mechanism of this effect is not known. However, because LAP
contains M6P residues and has been reported to bind to the
IGF-II/M6PR, we have postulated that latent TGF-/3 is localized
to the cell surface by binding the IGF-II/M6PR where it can be
efficiently activated by cell-associated plasmin. Third, the cross-
linking enzyme tissue transglutaminase is involved since both
nonspecific and specific inhibitors of this enzyme block activation
[35]. Thus, association of LLC to the matrix may be an important
preliminary step in activation.
It is not yet known why coculture is required. Although each
cell type produces all of the reactants described above, the levels
of specific molecules vary, and the combination of two cell types
may be important for this reason. Other activation systems with
similar characteristics have been reported. For example, cocultur-
ing carbon tetrachloride-exposed hepatic fat-storing cells with
sinusoidal endothelial cells results in TGF-p activation associated
with IGF-II/M6PR expression [52]. Also, retinoid-treated endo-
thelial cells and endotoxin-treated peritoneal macrophages can
activate TGF-p via a similar plasmin-based mechanism in mono-
culture [53, 54].
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Table 2. Activation mechanisms in cell culture systems
Cell type Stimulus Mechanism Reference
Endothelial cells retinoic acid
bFGF
plasmin
plasmin
[53]
[67]
Osteoblast glucorticoid proteases [601
Osteoclast (none) proteases [391
Chondrocyte Vitamin D1 vesicles [611
Gastric carcinoma (none) protease [751
Macrophage endotoxin
bleomycin
plasmin
plasmin
[541
[571
Other cell culture systems
There are over one hundred reports of cell culture systems in
which TGF-/3 is activated. In most of these reports, the mecha-
nism by which TGF-/3 is activated was not investigated. Most
frequently reported have been various cancer cell lines [55, 56],
monocytes and macrophages [54, 57], lymphocytes [58, 59], bone-
derived cells [39, 40, 60, 61], mesangial and renal tubular epithe-
ha! cells [62—65], fibroblasts [66], and vascular (endothelial [53,
67] and smooth muscle [68]) cells. In almost all of these systems
the cells do not activate TGF-p unless they are stimulated in some
way. For example, mesangial or proximal tubule cells in culture
have been reported to activate endogenous TGF-p following
exposure to angiotensin II [62], high glucose concentration [631,
thromboxane A2 [64] and low density lipoprotein [69]. Stimuli
that result in activation in more than one system include retinoic
acid [53, 70], sex hormones [55, 71, 72] and vitamin D3 [61, 73, 74].
In a small number of reports, the mechanism of activation has
been investigated, as shown in Table 2.
In vivo activation
Animal studies already indicate that inhibitors of active TGF-13
(such as blocking antibodies or decorin) can ameliorate the course
of diseases such as nephrosclerosis [76, 77]. An understanding of
TGF-/3 activation in vivo might lead to alternate therapies that
block pathologic activation. Grainger and colleagues [11] and
Barcellos-I-Ioff et al [12] have reported promising results on the
use of histochemical techniques to assess TGF-p activation in
vivo.
Grainger et al examined levels of active TGF-/3 in the vascular
walls of mice genetically engineered to overexpress lipoprotein
(a), which is associated with coronary atherosclerotic disease in
humans. They used a soluble type II TGF-13 receptor to localize
active TGF-f3, and attempted to avoid the activation of latent
TGF-J3 in the tissues by closely regulating the fixation process.
There was less active TGF-p in the vessel walls of mice overex-
pressing the lipoprotein. This decrease is consistent with a plas-
mm-mediated activation of TGF-f3 in the vessel wall, since
lipoprotein (a) displaces plasminogen from cell binding sites and
can block TGF-j3 activation in plasmin-dependent cell activation
systems [50].
Barcellos-Hoff et al used specific anti-TGF-13 antibodies to
examine tissue sections of irradiated mammary tissue. They
performed careful control studies using tumor masses formed by
injected cells that had been stably transfected to express either
latent or constitutively active TGF-f3 in order to identify antibod-
ies and fixation conditions in which active TGF-/3 is detected [78].
Their results indicate a rapid activation of TGF-13 after irradia-
tion, and a later sustained increase in activity. They hypothesize
that, because ionizing radiation activates TGF-/3 rapidly in vitro,
the initial surge of activation is a direct effect of the radiation.
They suggest that the later sustained increase is due to increased
tissue plasminogen activator (and hence plasmin).
Conclusion and future directions
We propose a general model of TGF-f3 activation. Latent
TGF-13 is targeted to the extracellular matrix by LTBP. A
truncated form of latent TGF-p is released from the matrix by the
action of one or more proteases on LTBP. Structural features of
LAP and/or LTBP allow the latent complex to associate with the
cell surface. Finally, latent TGF-/3 is activated by cell-associated
plasmin.
Much remains to be discovered about TGF-f3 activation. Any of
the steps proposed above could be modulated in ways yet to be
discovered. Other important mechanisms of physiological activa-
tion probably exist. What new studies might further the under-
standing of TGF-/3 activation?
(1.) Determining the three dimensional structure of LAP (and the
SLC). This may suggest regions of LAP available for protein-
protein interactions or proteolysis, and information about possible
conformational changes that might promote activation.
(2.) Developing in vivo systems for testing activation systems. The
systems described above represent good starting points and could
be extended by interfering with potential activating mechanisms.
(3.) Comparative studies of the three isoforms. Experiments to
date have mainly involved TGF-pl. The other two isoforms, which
are more dissimilar in the propeptide (LAP) region than in the
cytokine region, may have quite different modes of activation.
(4.) Determining the mechanism of association of LTBP to the
matrix. Indirect evidence suggests that tissue transglutaminase
cross-links LTBP to the matrix. Alternatively, the eight cysteine
domains, which are involved in other protein-protein interactions,
may be involved in bonding to the matrix. Studies are needed to
determine the mechanism of LTBP association to the matrix and
to identify the matrix proteins with which it interacts.
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